Lynozyfic, linvoseltamab-gcpt
Named-patient access overview. Lynozyfic is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Lynozyfic
Lynozyfic (linvoseltamab-gcpt) is manufactured by Regeneron and indicated for R/R multiple myeloma after >=4 prior therapies. It is a bispecific antibody approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Lynozyfic
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Lynozyfic for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Lynozyfic is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Lynozyfic in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Lynozyfic
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.